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Background: World Health Organization (WHO) criteria are commonly used to diagnose plasma cell myeloma
(PCM); however, these criteria are complex and require several laboratory parameters. For differentiating reactive
plasmacytosis from clonal plasma cell (PC) neoplasms such as PCM, it is important to accurately determine the
expression of cytoplasmic immunoglobulin light chains.
Methods: We retrospectively analyzed the records of 27 selected patients with PCM who underwent bone biopsies
for confirmative diagnosis according to WHO criteria. Twenty-three controls were also investigated. In the present
study, all the samples were analyzed using flow cytometry (FC) in the side scatter vs. CD38 histogram mode, and
the CD38-gated PC population was identified. Bivariate histograms of CD138/kappa and CD138/lambda were
assessed, and the ratios of dual-positive cells to the CD138+ PC population were calculated. The kappa/lambda ratio
was defined as the ratio of CD138/kappa to CD138/lambda.
Results: PCM cells were distinguished from normal PCs using cutoff levels between 0.76 and 1.5, at a sensitivity of
96.3% and specificity of 95.7%.
Conclusions: Three-color FC analysis is simple to perform and inexpensive, with clinically relevant data obtained
soon after the completion of FC measurements. The detection of the cytoplasmic kappa/lambda ratio of
CD38-gated CD138+ PCs may be a useful tool in the diagnosis of PCM. To the best of our knowledge, this report
represents the first diagnostic assessment of the cytoplasmic kappa/lambda ratio in CD38-gated CD138+ PCs using
FC analysis. This method may help in more simple, efficient, rapid, and accurate diagnosis of PCM.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1568085959771735
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Plasma cell myeloma (PCM) is a bone marrow (BM)-
based, multifocal plasma cell (PC) neoplasm associated
with the presence of M protein in serum and/or urine.
Most cases involve disseminated tumor cells in BM.
World Health Organization (WHO) criteria are usually
employed to diagnose PCM [1]. These criteria are based* Correspondence: in1304@poh.osaka-med.ac.jp
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distribution, and reproduction in any mediumon a combination of pathological, radiological, and clin-
ical features. However, the diagnostic criteria are com-
plex, and several laboratory parameters are required for
an accurate diagnosis. The diagnosis involves evaluating
the clinical burden of PC infiltration, analysis of radio-
logically detectable bone lesions, electrophoretic deter-
mination of monoclonal immunoglobulins (Igs), and
assessment of PCs in BM. Using retrospective analyses,
we investigated the diagnostic value of an abnormal
cytoplasmic kappa/lambda ratio of CD38-gated CD138+
PCs based on flow cytometry (FC) assessment. Wetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ratio that maximized the diagnostic sensitivity and speci-
ficity and minimized false-positive and false-negative
results.
Materials and methods
Case and control samples
We retrospectively analyzed the records of 27 patients
with PCM who underwent bone biopsies between 2000
and 2010 at the Osaka Medical College, Osaka, Japan.
Final diagnosis of PCM was established according to
WHO criteria. We obtained written consent from each
patient. Eleven males and 16 females whose ages ranged
from 47 to 85 years [mean ± standard deviation (SD),
66.2 ± 10.1 years] were included. Monoclonal compo-
nents of the myelomas in the patient group were IgA
type (n = 5), IgG type (n = 16), IgM type (n = 2), Bence-
Jones type (n = 3), and nonsecretory type (n = 1); mono-
clonal components of the Ig light chain (LC) were kappa
type (n = 9) and lambda type (n = 17).
For the control group, BM samples were obtained and
examined from 23 patients who were recovering from
inflammatory disorders and healthy people who were
initially suspected as having hematological diseases
and underwent examination for the same. (12 males
and 11 females; age range, 29–81 years; mean ± SD,
62.5± 12.9 years). The monoclonal components in their
serum and urine were undetectable by immunofixation
electrophoresis.
Sample preparation and FC analysis
For preparation of the cell suspensions, BM samples
were collected in EDTA anticoagulant. All the samples
were washed twice in phosphate-buffered saline (PBS)
and resuspended in PBS at a concentration of approxi-
mately 2 × 106 cells/ml. The cells were resuspended in
100 μl of Reagent 1 (fixation) (IntraPrep™; Beckman
Coulter, Brea, CA, USA) for 15 min at room
temperature and washed in PBS. After washing, per-
meabilization was induced by incubation in 100 μl of
Reagent 2 (permeability), with the remaining erythro-
cytes being lysed simultaneously. The samples were
stained for 30 min at 4°C with either phycoerythrin cya-
nine 5.1 (PC5)-conjugated CD38 (J.33; Beckman
Coulter), phycoerythrin-conjugated CD138 (HIB19;
Becton Dickinson, San Jose, CA, USA), fluorescein
isothiocyanate (FITC)-conjugated kappa [goat F(ab0)2
anti-human kappa; Biosource, Camarillo, CA, USA], or
lambda [goat F(ab0)2 anti-human lambda; BioSource
Corporation, Bethesda, MD, USA]. Negative control
samples were stained for 30 min at 4°C with FITC-
conjugated rat antihuman Ig (LODNP1; Coulter) and
PC5-conjugated rat antihuman Ig (LODNP1; Coulter)
(Table 1). All the samples were rinsed twice in PBS andanalyzed on a flow cytometer (EPICS XL; Coulter) using
System II software, version 3.0 (Coulter). Approximately
10,000 cells were analyzed.
The first step was to exclude any debris and fat cells
on the forward scatter (FSC)/side scatter (SSC) histo-
grams. All the samples were analyzed in the SSC vs.
CD38 histogram mode with the CD38-gated PC pop-
ulation being identified by its characteristic bright
CD38 expression. Following this, CD138/kappa and
CD138/lambda were assessed on bivariate histograms,
and the ratios of dual-positive cells to the CD138+ PC
population were calculated (Figure 1). The kappa/
lambda ratio was defined as the ratio of CD138/kappa to
CD138/lambda.
Statistical analysis
The number of observations, means, SDs, medians, min-
imums, and maximums for continuous variables as well
as the number, percentage, sensitivity, and specificity for
categorical data were calculated. All analyses were per-
formed using SPSS software (ver. 18 for Windows; SPSS
Japan Inc., Tokyo, Japan). The kappa/lambda ratios of
the 23 healthy individuals were limited to a narrow
range of 0.76 to 8.80, whereas those of the 27 patients
were distributed over a wider range of 0.00102 to 478.5.
Thus, by choosing two levels, l and u, with l <u, to
distinguish the patients from controls, we could create a
frequency table with two rows and three columns
(Table 2) and define (nd +nb +nf)/50 as the “error rate”
for disease diagnosis using the kappa/lambda ratio. We
decided that the values for both the lower and upper cut-
off levels would be those with the lowest error rate among
the error rates of 5000 frequency tables created by moving
l (0–0.99 by 0.01) and u (1.1–6.0 by 0.1), independently.
We also computed the sensitivity and specificity of these
cutoff values. All the procedures were performed using R
statistical software (http://www.Rproject.org). R provides
a wide variety of statistical analyses and is highly exten-
sible. R is designed around a true computer language
and allows users to add additional functionality by de-
fining new functions.
Results
The positive cell ratios were 52.7% − 99.4% (mean± SD,
82.7%± 20.5%) for kappa and 0.20%− 52.2% (mean± SD,
16.1%± 20.1%) for lambda in the patients with kappa-
type PCM (n= 9). The positive cell ratios were
0.1%− 24.5% (mean ± SD, 5.4%± 6.5%) for kappa and
67.7%− 99.6% (mean± SD, 94.2% ± 7.7%) for lambda in
the patients with lambda-type PCM (n= 17). The posi-
tive cell ratios were 6.5% for kappa and 96.6% for
lambda in the patient with nonsecretory-type PCM
(n= 1). The range of the kappa/lambda ratio was
1.00− 478.5 (mean ± SD, 84.20 ± 156.84) in the patients
Table 1 List of antibodies/probes
Antibody Probe Source
CD38 J.33 Becton Dickinson, San Jose, CA, USA
CD138 HIB19 Becton Dickinson, San Jose, CA, USA
Kappa goat F(ab’)2 anti-human kappa BioSource Corporation, Bethesda, MD, USA
Lambda goat F(ab’)2 anti-human lambda BioSource Corporation, Bethesda, MD, USA
Immunoglobulin LODNP1 Becton Dickinson, San Jose, CA, USA
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0.063 ± 0.089) in the patients with lambda-type PCM
(n=17), and 0.067 in the patient with nonsecretory-type
PCM (n=1) (Table 3).
In the controls, the positive cell ratio ranged between
32.4% and 90.2% (mean ± SD, 62.5%± 12.9%) for kappa
and between 10.2% and 56.2% (mean ± SD, 43.9%± 9.0%)
for lambda. The range of the kappa/lambda ratio in the
controls was 0.76− 8.80 (mean ± SD, 1.57 ± 1.58).
Among the 27 patients diagnosed with PCM, 26 had
kappa/lambda ratios of >1.5 and <0.76. The kappa/
lambda ratio was ≥0.76 and ≤1.5 in the remaining pa-
tient with PCM. In the 23 controls, 22 had kappa/
lambda ratios of ≥0.76 and ≤1.5, whereas the remaining
control had a ratio >1.5 (Table 4). We have followed this
patient’s clinical course for 5 years, and the patient has
remained healthy and does not satisfy WHO criteria for
PCM. Thus, PCM cells were distinguished from normal
PCs by cutoff levels between 0.76 and 1.5, at a sensitivity













Figure 1 Three-color flow cytometry analysis. Side scatter vs. CD38 hist
(phycoerythrin) and kappa or lambda (fluorescein isothiocyanate) (right).Discussion
The accurate determination of cytoplasmic Ig (cIg) LC
expression is important for differentiating reactive plas-
macytosis from clonal PC dysplasia. The former is
caused by polyclonal proliferation of PCs, whereas the
latter is caused by clonal proliferation of PCs with LC
restriction. At present, several methods are available for
measuring cIg LCs, including immunohistochemical
staining, FC, and immunofluorescent staining [2]. Based
on commonly used criteria, LC restriction has been
defined as a kappa/lambda ratio >4.0 or <0.5 [3-5]. How-
ever, these studies showed cIg LC restriction in patients
with B-cell lymphoma and B-cell chronic lymphocytic
leukemia but not in those with PCM. One report pro-
posed threshold values for the ratio of cytoplasmic kappa
to lambda LCs in PCs for detecting monoclonality in
addition to listing criteria for discriminating between
PCM and benign reactive plasmacytosis using immuno-
histological analyses [6]. That study determined the
cytoplasmic kappa/lambda ratio in PCs to be 0.4–3.5 forbda CD38/CD138/Lambda
ppa CD38/CD138/Kappa
ogram mode with CD38 gating (left). Bivariate histogram of CD138
Table 2 Frequency table in statistical analyses
x< l l≤ x≤ u u< x Total
Plasma cell myeloma na nb nc 27
Control nd ne nf 23
Table 4 Results of frequency table in statistical analysis
x < 0.76 0.76≤ x≤ 1.5 1.5 < x Total
Plasma cell myeloma 18 1 8 27
Control 0 22 1 23
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ever, the study did not define the definitive limits of an
abnormal kappa/lambda ratio in the diagnostic process.
In addition, the PC infiltrate in biopsies and smears was
morphologically assessed using only hematoxylin–eosin
staining; therefore, the detection of PCs may have been
ambiguous.
FC has evolved from a promising new technology to
an indispensable, rapid, and sensitive tool for diagnosing
hematological malignancies. Many new antibodies,
improved gating strategies, and routine use of multipara-
meter techniques have dramatically improved the diag-










IgA lambda IIIA 66.1% 0.0107
IgA lambda IIIB 28.4% 0.0514
IgA lambda IIIA 63.3% 0.1045
IgA lambda IIIA 43.5% 0.1747
IgA kappa IIA 88.2% 1.526
IgG lambda IIB 78.1% 0.00102
IgG lambda IIIB 30.3% 0.00703
IgG lambda IIIA 59.8% 0.00834
IgG lambda IIIA 20.7% 0.00127
IgG lambda IIB 66.1% 0.0161
IgG lambda IIB 59.9% 0.0115
IgG lambda IIIB 32.2% 0.0232
IgG lambda IIIA 40.1% 0.0418
IgG lambda IIIA 20.2% 0.0430
IgG lambda IIIB 20.6% 0.0509
IgG lambda IIIA 12.3% 0.0604
IgG kappa IIIA 13.4% 1.009
IgG kappa IA 37.2% 1.522
IgG kappa IA 35.0% 15.16
IgG kappa IIIb 20.4% 24.02
IgG kappa IIIA 9.8% 478.5
IgM kappa IIIA 59.5% 16.74
IgM kappa IIIA 10.5% 165.1
Bence-Jones lambda IIA 6.1% 0.0944
Bence-Jones lambda IIIA 67.0% 0.361
Bence-Jones kappa IIA 76.8% 52.66
Non-secretary lambda IIIB 41.6% 0.0672mandatory for the diagnosis and monitoring of acute
leukemias and chronic lymphoproliferative disorders. In
contrast, for PCM, the use of multiparametric FC in
many clinical diagnostic laboratories is currently
restricted to clinical research studies and the differential
diagnosis of unusual cases [7-9]. PCM has traditionally
been difficult to assess by FC, mainly because of the loss
of most B lineage-specific antigens and surface Igs dur-
ing maturation to PCs. A recent study using a multi-
parameter approach with membrane permeabilization
achieved a sensitivity of less than 1% [10]. The gener-
ation and identification of markers allows the unequivo-
cal identification of PCs among other hematopoietic cell
types such as CD138, and the identification of aberrant
PC phenotypes enables to discriminate between normal
and neoplastic PCs. The identification of an accurate
gating strategy is a critical component of a reproducible
and sensitive immunophenotypical assay for analyzing
PCs. Various approaches based on CD38, CD138, and/or
CD45 expression have been used. The majority of cen-
ters report a gating strategy using combined CD38,
CD138, and light-scatter characteristics. Notably, there
is no formal published consensus method for gating
PCs. The percentage of myeloma cells or PCs in BM
mononuclear cells based on morphologic examination is
almost the same as that of CD38-bright fractions mea-
sured by FC. It has therefore been confirmed that
normal PCs and myeloma cells are located in the CD38-
bright fractions stained with CD38 antibodies [11].
Although CD38 is a common marker expressed on vari-
ous different cell populations such as T, B, and natural
killer cells as well as PCs, high-density expression of
CD38 on the cell surface is also a characteristic feature
of normal and malignant PCs. CD38 measured as a
single marker using FC can therefore help distinguish
normal and malignant PCs from other cell types [12].
PCs also typically express weak or absent CD45. The
use of two-color analysis with CD38 and CD45 can reli-
ably identify PCs in peripheral blood and BM
[13]. Neoplastic PCs are traditionally identified by their
CD38+ CD45−/dim staining pattern on FC histograms
[11,14]. LC restriction has also been defined by this
method, with 87% of PCM cases complying with com-
monly used criteria for B-cell neoplasms (i.e., kappa/
lambda ratios >4.0 or <0.5) (2, 3-5). However, it is clear
that CD38+ CD45−/dim gating may fail to identify mye-
loma mainly or partly composed of CD45+ PCs [15]. In
addition, neoplastic PCs typically express CD38 at a
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guishable from contaminating T or B cells [16]. Imma-
ture or precursor B lymphocytes are also located in
CD38-bright fractions stained with CD38 antibodies,
whereas neoplastic PCs may be indistinguishable
from immature or precursor B lymphocytes. CD138
(syndecan-1) is a transmembrane heparin sulfate
proteoglycan that is typically expressed by PCs and not
by T cells, B cells, or immature/precursor B lymphocytes
[17]. Assessment of cytoplasmic kappa/lambda expression by
FC is important for demonstrating clonality at presentation
and is appropriate for the assessment of a stringent complete
remission according to IMWG criteria [18]. Standard com-
mercial fixation and permeabilization kits have been reported
to be suitable for the assessment of cytoplasmic kappa/
lambda detection, and users have not reported any specific
advantages or disadvantages of the kits available from differ-
ent companies. Therefore, the assessment of cytoplasmic
kappa/lambda expression by FC is easy to routinize [19]. We
attempted to identify PCs using three-color analysis of
CD38, CD138, and LCs (kappa and lambda). Next, we inves-
tigated the decision limits for an abnormal kappa/lambda
ratio of CD38-gated CD138+ cells using three-color FC of
CD38, CD138, and LCs. By advances in FCM, the identifica-
tion of aberrant PC phenotypes that enable us to discrimin-
ate between normal and neoplastic PCs has allowed us to
identify, characterize, and enumerate neoplastic PCs even
when few cells are present. There have been no formal stud-
ies to identify the minimum requirements for reproducible
detection of minimal residual disease, and further investiga-
tion is required to identify a common panel. However, based
on reported studies, a panel containing CD19 and CD56
would be applicable to at least 90% of patients, with
the markers CD20, CD117, CD28, and CD27 likely to
increase this applicability to more than 95% of patients. In
addition, several participants analyzed CD81 and CD20068
and suggested that these markers should be assessed further
[19-23]. Combined assessment of clonality and basic immu-
nophenotype may be useful for screening at diagnosis and
follow-up. However, these analyses are more difficult and
costly, and it is difficult to routinize these analyses for the
screening of newly diagnosed usual PCM in general
hospitals.
To the best of our knowledge, our report is the first
diagnostic assessment of the cytoplasmic kappa/lambda
ratio in CD38-gated CD138+ PCs using FC analysis. This
study showed that a diagnostic kappa/lambda ratio of
<0.76 and >1.5 has a sensitivity of 96.3% and a specificity
of 95.7%. Three-color FC analysis is simple to perform
and inexpensive, with clinically relevant data obtained
soon after completion of the FC measurements. Taking
all these factors into consideration, the correct diagnosis
of PCM can be achieved more simply, efficiently, and
rapidly by this method. This method may improve theaccuracy of the diagnostic kappa/lambda ratio deter-
mined directly in PCs, and it may be a useful tool for
the diagnosis of PCM.
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